SCHEMBL8320853

SCHEMBL8320853

Cc1cccc2c1c(C(=O)O)nn2C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.40
ALDH1A1 P00352 4/20 0.40
KDM4E B2RXH2 4/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPK13 O15264 1/20 0.40
EIF2AK2 P19525 1/20 0.40
MAPK12 P53778 1/20 0.40
MAPK11 Q15759 1/20 0.40
MAPK14 Q16539 1/20 0.40
MAPT P10636 4/20 0.39
LMNA P02545 1/20 0.39
RARG P13631 1/20 0.39
RORC P51449 1/20 0.39
HTR3A P46098 2/20 0.38
PKM P14618 1/20 0.38
GAA P10253 1/20 0.37
CMA1 P23946 2/20 0.37
HPGD P15428 2/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15517124 0.85 ELANE (0.41) NAMPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL23563223 0.82 KDM4E (0.39) ALDH1A1KDM4EMEN1KMT2AMAPK13
SCHEMBL28361133 0.82 ALDH1A1 (0.51) ALDH1A1KDM4EMEN1KMT2AMAPK13
SCHEMBL23809325 0.81 KDM4E (0.38) ALDH1A1KDM4EMEN1KMT2AMAPK13
SCHEMBL21816286 0.80 MAPT (0.55) ALDH1A1KDM4EMEN1KMT2AMAPT
SCHEMBL31429464 0.75 HTR3A (0.41) MEN1KMT2AMAPTRARGRORC
SCHEMBL12536276 0.74 MAPK13 (0.42) NAMPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL28809240 0.74 KDM4E (0.33) ALDH1A1KDM4EMEN1KMT2AMAPT
SCHEMBL31729301 0.74 KDM4E (0.33) ALDH1A1KDM4EMEN1KMT2AMAPT
SCHEMBL31123882 0.74 KDM4E (0.33) ALDH1A1KDM4EMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230330099-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS VANDERBILT UNIVERSITY 2023-10-19 US disclosed
US-20230330099-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS VANDERBILT UNIVERSITY 2023-10-19 US disclosed
US-5955470-A Derivatives of amide analogs of certain methano bridged quinolizines MERRELL PHARMACEUTICALS, INC. (US) 1999-09-21 US disclosed
EP-0517984-A1 Derivatives of amide analogs of certain methano bridged quinolizines MERRELL DOW PHARMACEUTICALS INC. (US) 1992-12-16 EP disclosed
EP-0518767-A2 Derivatives of amide analogs of certain methano bridged quinolizines MERRELL PHARMACEUTICALS INC. (US) 1992-12-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230330099-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, BCL9 NAMPT 3421/4885ALDH1A1 2556/4885KDM4E 1156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.